UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology. UCB aims to be the patient-preferred biotech leader by delivering medicines and solutions that improve lives. The company is headquartered in Brussels, Belgium, with approximately 7,500 employees in over 40 countries. UCB is listed on Euronext Brussels (symbol: UCB).